SERA PROGNOSTICS, INC.
SERANasdaq
$2.05
↓ -6.8%Jul 17 close · end-of-day
Price
1Y↓ -31.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$103.0M
Enterprise Value
$55.6M
P/E
—
P/S
1807.6
P/B
1.5
EV/EBITDA
—
PEG
—
FCF Yield
-26.8%
Dividend Yield
—
Revenue (TTM)
$57,000.00
Net Income (TTM)
-$32.1M
Free Cash Flow (TTM)
-$27.6M
Gross Margin
—
Operating Margin
-64235.1%
Net Margin
-56386.0%
ROE
-47.5%
ROIC
-143.1%
Debt / Equity
—
Net Cash
$47.4M
Return 1Y
-31.7%
Company profile
Sera Prognostics, Inc. develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
- CEO
- Gregory C. Critchfield
- Sector
- Services
- Industry
- Healthcare
- Employees
- 120
- Headquarters
- Utah
- Website
- www.seraprognostics.com
Management & directors
- Aerts AustinChief Financial Officer
- Anderson Dyaarl Lee Jr.Chief Commercial Officer
- Inglis Tiffany Eul DavisChief Medical Officer
- Jackson BenjaminGeneral Counsel
- Lindgardt ZhenyaChief Executive Officer
- Boniface John J.Chief Scientific Officer
- Harrison Robert GardnerChief Information Officer
- Kearney PaulChief Data Officer
Roles derived from SEC Form 4 filings.
Earnings
SERA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$14,000.00↓ -63.2%
Diluted EPS-$0.17↓ -15.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $25,000.00 | $82,000.00 | $268,000.00 | $306,000.00 | $77,000.00 | $81,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.0M | -$35.4M | -$45.7M | -$39.8M | -$36.6M | -$36.5M |
| Net income | -$19.8M | -$35.0M | -$44.2M | -$36.2M | -$32.9M | -$31.9M |
| Diluted EPS | -$12.76 | -$2.33 | -$1.43 | -$1.16 | -$0.99 | -$0.67 |
| Operating cash flow | -$16.9M | -$31.6M | -$34.6M | -$27.2M | -$14.2M | -$25.6M |
| Free cash flow | -$17.0M | -$32.9M | -$35.4M | -$27.3M | -$14.2M | -$26.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -71884.0% | -43164.6% | -17034.3% | -13013.4% | -47577.9% | -45066.7% |
| Net margin | -79392.0% | -42693.9% | -16487.3% | -11843.8% | -42724.7% | -39417.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24,000.00 | $29,000.00 | $24,000.00 | $38,000.00 | $17,000.00 | $16,000.00 | $10,000.00 | $14,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.3M | -$8.9M | -$9.4M | -$9.3M | -$9.3M | -$9.0M | -$9.0M | -$9.4M |
| Net income | -$8.3M | -$7.9M | -$8.6M | -$8.2M | -$8.0M | -$7.8M | -$7.9M | -$8.4M |
| Diluted EPS | -$0.25 | -$0.24 | -$0.25 | -$0.20 | -$0.16 | -$0.16 | -$0.15 | -$0.17 |
| Operating cash flow | -$5.9M | -$7.0M | -$6.3M | -$7.6M | -$5.5M | -$6.5M | -$6.1M | -$8.8M |
| Free cash flow | -$5.9M | -$7.0M | -$6.3M | -$7.6M | -$5.8M | -$6.6M | -$6.5M | -$8.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -38554.2% | -30558.6% | -39262.5% | -24342.1% | -54823.5% | -56125.0% | -89540.0% | -66857.1% |
| Net margin | -34595.8% | -27306.9% | -35745.8% | -21544.7% | -47329.4% | -48837.5% | -78810.0% | -59992.9% |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Phillips Joshua | Award | 22,426 | $0.00 | $0.00 | filing |
| 2026-07-10 | Phillips Joshua | Award | 2,260 | $0.00 | $0.00 | filing |
| 2026-07-10 | Mirza Mansoor Raza | Award | 22,426 | $0.00 | $0.00 | filing |
| 2026-07-10 | Mirza Mansoor Raza | Award | 1,771 | $0.00 | $0.00 | filing |
| 2026-07-10 | Lawrence Sandra AJ | Award | 22,426 | $0.00 | $0.00 | filing |
| 2026-07-10 | Lawrence Sandra AJ | Award | 2,276 | $0.00 | $0.00 | filing |
| 2026-07-10 | Kamdar Kim P. | Award | 22,426 | $0.00 | $0.00 | filing |
| 2026-07-10 | Kamdar Kim P. | Award | 3,421 | $0.00 | $0.00 | filing |
| 2026-07-10 | CRITCHFIELD GREGORY C | Award | 22,426 | $0.00 | $0.00 | filing |
| 2026-07-10 | CRITCHFIELD GREGORY C | Award | 1,594 | $0.00 | $0.00 | filing |
| 2026-07-10 | Capone Mark Christopher | Award | 42,404 | $0.00 | $0.00 | filing |
| 2026-07-10 | Capone Mark Christopher | Award | 1,975 | $0.00 | $0.00 | filing |
| 2026-07-10 | Barlow Jane F | Award | 22,426 | $0.00 | $0.00 | filing |
| 2026-07-10 | Barlow Jane F | Award | 1,949 | $0.00 | $0.00 | filing |
| 2026-06-11 | Lindgardt Zhenya· Chief Executive Officer | Sale | 6,990 | $2.01 | $14,049.90 | filing |
| 2026-06-11 | Anderson Dyaarl Lee Jr.· Chief Commercial Officer | Sale | 4,739 | $2.01 | $9,525.39 | filing |
| 2026-06-11 | Jackson Benjamin· General Counsel | Sale | 2,179 | $2.01 | $4,379.79 | filing |
| 2026-06-11 | Aerts Austin· Chief Financial Officer | Sale | 2,037 | $2.01 | $4,094.37 | filing |
| 2026-06-11 | Inglis Tiffany Eul Davis· Chief Medical Officer | Sale | 362 | $2.01 | $727.62 | filing |
| 2026-06-09 | Lindgardt Zhenya· Chief Executive Officer | Sale | 20,755 | $2.08 | $43,170.40 | filing |
| 2026-06-09 | Aerts Austin· Chief Financial Officer | Sale | 5,440 | $2.08 | $11,315.20 | filing |
| 2026-06-08 | Lawrence Sandra AJ | Sale | 1,560 | $2.15 | $3,354.00 | filing |
| 2026-05-29 | Jackson Benjamin· General Counsel | Award | 5,000 | $1.84 | $9,200.00 | filing |
| 2026-05-29 | Anderson Dyaarl Lee Jr.· Chief Commercial Officer | Award | 3,168 | $1.84 | $5,829.12 | filing |
| 2026-03-12 | Lindgardt Zhenya· Chief Executive Officer | Award | 154,440 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.